MRNA's three largest insider shareholders as of April 17, 2026 are Robert Langer (Director, 11.47Mn shares), Noubar Afeyan (Director, 9.46Mn shares), Stephane Bancel (Chief Executive Officer, 9.21Mn shares).
| Holder | Position | Shares (Direct) | Shares (Indirect) | Report Date |
|---|---|---|---|---|
| Robert Langer | - | 11,467,664 | 0 | 02 May, 2022 |
| Noubar Afeyan | - | 0 | 9,459,282 | 11 Jun, 2024 |
| Stephane Bancel | Chief Executive Officer | 0 | 9,210,686 | 04 Mar, 2025 |
| Stephane Bancel | Chief Executive Officer | 6,187,791 | 0 | 13 Feb, 2026 |
| Noubar Afeyan | - | 0 | 5,816,657 | 13 May, 2022 |
| Noubar Afeyan | - | 2,224,015 | 0 | 02 Aug, 2024 |
| Stephen Hoge | President | 1,477,997 | 0 | 03 Mar, 2026 |
| Paul Sagan | - | 0 | 312,027 | 04 Mar, 2025 |
| Shannon Thyme Klinger | Chief Legal Officer | 65,782 | 0 | 06 Mar, 2026 |
| James M Mock | Chief Financial Officer | 57,748 | 0 | 06 Apr, 2026 |
| Stephen Berenson | - | 22,203 | 0 | 07 May, 2024 |
| Francois Nader | - | 20,607 | 0 | 12 May, 2022 |
| Francois Nader | - | 20,607 | 0 | 12 May, 2022 |
| Paul Sagan | - | 0 | 14,951 | 15 Oct, 2021 |
| Juan Andres | - | 12,803 | 0 | 30 Dec, 2022 |
| Noubar Afeyan | - | 0 | 3,924 | 15 Dec, 2025 |
| Arpa Garay | Chief Commercial Officer | 3,690 | 0 | 07 Dec, 2023 |
| Elizabeth G Nabel | - | 3,084 | 0 | 01 May, 2025 |
| Elizabeth G Nabel | - | 3,084 | 0 | 01 May, 2025 |
| David W Meline | Chief Financial Officer | 2,857 | 0 | 11 Aug, 2022 |
| Sandra Horning | - | 2,352 | 0 | 01 May, 2025 |
| David M. Rubenstein | - | 1,527 | 0 | 06 Aug, 2025 |
| David M. Rubenstein | - | 1,527 | 0 | 06 Aug, 2025 |
| Abbas Hussain | - | 1,515 | 0 | 11 Dec, 2025 |
| Paul Burton | Chief Medical Officer | 954 | 0 | 08 Nov, 2022 |
| Elizabeth E Tallett | - | 703 | 0 | 02 May, 2022 |
| Elizabeth E Tallett | - | 703 | 0 | 02 May, 2022 |
| Paul Sagan | - | 703 | 0 | 02 May, 2022 |
* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.
| Transaction Date | Insider Name | Security Class | Transaction Type | Shares Traded | Price | Shares Remaining | Ownership | Code |
|---|---|---|---|---|---|---|---|---|
| 02 Apr, 2026 | James M Mock | Common Stock | A | 1,453 | - | 58,451 | D | M |
| 02 Apr, 2026 | James M Mock | Common Stock | D | 703 | $50.03 | 57,748 | D | F |
| 02 Apr, 2026 | James M Mock | Restricted Stock Units | D | 1,453 | $0.00 | 2,906 | D | M |
| 05 Mar, 2026 | Shannon Thyme Klinger | Common Stock | A | 11,797 | - | 71,486 | D | M |
| 05 Mar, 2026 | James M Mock | Common Stock | A | 11,797 | - | 62,702 | D | M |
| 05 Mar, 2026 | Shannon Thyme Klinger | Common Stock | D | 5,704 | $57.80 | 65,782 | D | F |
| 05 Mar, 2026 | James M Mock | Common Stock | D | 5,704 | $57.80 | 56,998 | D | F |
| 05 Mar, 2026 | Shannon Thyme Klinger | Restricted Stock Units | D | 11,797 | $0.00 | 129,774 | D | M |
| 05 Mar, 2026 | James M Mock | Restricted Stock Units | D | 11,797 | $0.00 | 129,774 | D | M |
| 27 Feb, 2026 | Stephen Hoge | Common Stock | A | 652 | - | 1,458,079 | D | M |
| 27 Feb, 2026 | James M Mock | Common Stock | A | 329 | - | 45,553 | D | M |
| 27 Feb, 2026 | Shannon Thyme Klinger | Common Stock | A | 233 | - | 54,760 | D | M |
| 27 Feb, 2026 | James M Mock | Common Stock | D | 160 | $51.71 | 45,393 | D | F |
| 27 Feb, 2026 | Shannon Thyme Klinger | Common Stock | D | 113 | $51.71 | 54,647 | D | F |
| 27 Feb, 2026 | Stephen Hoge | Common Stock | D | 316 | $51.71 | 1,457,763 | D | F |
| 27 Feb, 2026 | Shannon Thyme Klinger | Common Stock | A | 329 | - | 54,976 | D | M |
| 27 Feb, 2026 | Stephen Hoge | Common Stock | A | 611 | - | 1,458,374 | D | M |
| 27 Feb, 2026 | James M Mock | Common Stock | A | 774 | - | 46,167 | D | M |
| 27 Feb, 2026 | Shannon Thyme Klinger | Common Stock | D | 160 | $51.71 | 54,816 | D | F |
| 01 Mar, 2026 | Stephane Bancel | Stock Option (Right to Buy) | A | 250,932 | $0.00 | 250,932 | D | A |